MOLECULAR TEMPLATES INC (MTEM) Stock Price & Overview
NASDAQ:MTEM • US6085502085
Current stock price
The current stock price of MTEM is 0.1072 USD. Today MTEM is down by -23.43%. In the past month the price decreased by -73.31%. In the past year, price decreased by -97.13%.
MTEM Key Statistics
- Market Cap
- 705.376K
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -2.70
- Dividend Yield
- N/A
MTEM Stock Performance
MTEM Stock Chart
MTEM Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to MTEM. When comparing the yearly performance of all stocks, MTEM is a bad performer in the overall market: 99.95% of all stocks are doing better.
MTEM Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to MTEM. MTEM scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
MTEM Earnings
On November 11, 2024 MTEM reported an EPS of -1.23 and a revenue of 572.00K. The company beat EPS expectations (16.26% surprise) and beat revenue expectations (30.41% surprise).
MTEM Forecast & Estimates
7 analysts have analysed MTEM and the average price target is 18.36 USD. This implies a price increase of 17026.87% is expected in the next year compared to the current price of 0.1072.
For the next year, analysts expect an EPS growth of -92.81% and a revenue growth -78.76% for MTEM
MTEM Groups
Sector & Classification
MTEM Financial Highlights
Over the last trailing twelve months MTEM reported a non-GAAP Earnings per Share(EPS) of -2.7. The EPS increased by 78.35% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -58.52% | ||
| ROE | -219.7% | ||
| Debt/Equity | 0 |
MTEM Ownership
MTEM Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.93 | 369.265B | ||
| AMGN | AMGEN INC | 15.01 | 187.564B | ||
| GILD | GILEAD SCIENCES INC | 15.85 | 173.439B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.4 | 111.445B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.32 | 80.543B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 44.27 | 42.286B | ||
| INSM | INSMED INC | N/A | 35.012B | ||
| NTRA | NATERA INC | N/A | 29.477B | ||
| BIIB | BIOGEN INC | 10.72 | 26.026B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.74 | 24.756B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.643B | ||
| MRNA | MODERNA INC | N/A | 19.431B | ||
| INCY | INCYTE CORP | 12.39 | 19.091B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About MTEM
Company Profile
Molecular Templates, Inc. engages in the discovery, development, and commercialization of biologic therapeutics for the treatment of cancers and other serious diseases. The company is headquartered in Austin, Texas and currently employs 62 full-time employees. The company went IPO on 2005-02-04. The Company’s proprietary drug platform technology, known as engineered toxin bodies (ETBs), leverages the resident biology of a genetically engineered form of Shiga-like Toxin A subunit to create novel therapies with potent and differentiated mechanisms of action for cancer. Its product pipeline includes MT-6402, MT-8421 and MT-0169. MT-6402 is an ETB consisting of a single chain variable fragments (scFv), with affinity for PD-L1, fused to the enzymatically active de-immunized SLTA and a HLA-A*02 class I antigen derived from the human cytomegalovirus (HCMV) pp65 protein. MT-8421, its ETB targeting CTLA-4, along with MT-6402. MT-0169 is designed to destroy CD38+ tumour cells through internalization of CD38 and cell destruction via a novel mechanism of action (enzymatic ribosomal destruction and immunogenic cell death).
Company Info
IPO: 2005-02-04
MOLECULAR TEMPLATES INC
9301 Amberglen Blvd, Suite 100
Austin TEXAS 78729 US
CEO: Eric E. Poma
Employees: 62
Phone: 15128961555
MOLECULAR TEMPLATES INC / MTEM FAQ
What does MOLECULAR TEMPLATES INC do?
Molecular Templates, Inc. engages in the discovery, development, and commercialization of biologic therapeutics for the treatment of cancers and other serious diseases. The company is headquartered in Austin, Texas and currently employs 62 full-time employees. The company went IPO on 2005-02-04. The Company’s proprietary drug platform technology, known as engineered toxin bodies (ETBs), leverages the resident biology of a genetically engineered form of Shiga-like Toxin A subunit to create novel therapies with potent and differentiated mechanisms of action for cancer. Its product pipeline includes MT-6402, MT-8421 and MT-0169. MT-6402 is an ETB consisting of a single chain variable fragments (scFv), with affinity for PD-L1, fused to the enzymatically active de-immunized SLTA and a HLA-A*02 class I antigen derived from the human cytomegalovirus (HCMV) pp65 protein. MT-8421, its ETB targeting CTLA-4, along with MT-6402. MT-0169 is designed to destroy CD38+ tumour cells through internalization of CD38 and cell destruction via a novel mechanism of action (enzymatic ribosomal destruction and immunogenic cell death).
What is the stock price of MOLECULAR TEMPLATES INC today?
The current stock price of MTEM is 0.1072 USD. The price decreased by -23.43% in the last trading session.
Does MTEM stock pay dividends?
MTEM does not pay a dividend.
How is the ChartMill rating for MOLECULAR TEMPLATES INC?
MTEM has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What sector and industry does MOLECULAR TEMPLATES INC belong to?
MOLECULAR TEMPLATES INC (MTEM) operates in the Health Care sector and the Biotechnology industry.
What is the employee count for MTEM stock?
MOLECULAR TEMPLATES INC (MTEM) currently has 62 employees.
What is MOLECULAR TEMPLATES INC worth?
MOLECULAR TEMPLATES INC (MTEM) has a market capitalization of 705.38K USD. This makes MTEM a Nano Cap stock.